Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
- PMID: 32277907
- PMCID: PMC7252196
- DOI: 10.1016/S1470-2045(20)30226-6
Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
References
-
- Vignot S, Martin M, Albin N, Schurtz C, Chapel E. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety. Ann Oncol. 2019;30:1694–1696. - PubMed
-
- Curigliano G. The treatment of patients with cancer and containment of COVID-19: experiences from Italy. March 17, 2020. https://dailynews.ascopubs.org/do/10.1200/ADN.20.200068/full/ - DOI
-
- US Food and Drug Administration FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: guidance for industry, investigators, and institutional review boards. March 27, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents...
-
- Instituto Nacional de Vigilancia de Medicamentos y Alimentos Lineamientos investigación clínica coronavirus (COVID-19) March 17, 2020. https://www.invima.gov.co/web/guest/lineamientos-investigacion-clinica-c...
MeSH terms
LinkOut - more resources
Full Text Sources
Medical